July 24, 2026

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

Scrip Code: 543349

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

NSE Symbol: ACUTAAS

Subject: Investor Presentation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation on financial results for the first quarter ended as on June 30, 2026 and other business matters.

This Investor Presentation will also be available on the website of the Company www.acutaas.com.

Kindly take the same on record.

Yours faithfully,
For, ACUTAAS CHEMICALS LIMITED

EKTA KUMARI SRIVASTAVA
Digitally signed by EKTA KUMARI SRIVASTAVA
Date: 2026.07.24 13:01:27 +05'30'

ACUTAAS CHEMICALS LIMITED

Ekta Kumari Srivastava
Company Secretary & Compliance Officer

Encl: Presentation

ACUTAAS®

You and us: chemistry's apex

EARNINGS PRESENTATION

JULY 2026

www.acutaas.com

Management Commentary

Mr. Naresh Patel

Executive Chairman and Managing Director

"We have started the year on a strong note, with revenue from operations growing 59.1% YoY to Rs. 3,297 mn – reflecting the agility of our business model and our ability to keep delivering to customers, on time and without compromise.

We have also been certified as a Great Place to Work – a recognition of the culture of trust, collaboration and pride our people have built, and a proud validation of the team behind all we have achieved.

We have further received the Responsible Care certification from the Indian Chemical Council – the industry's commitment to the highest standards of safety, health and environmental performance – reaffirming our resolve to grow responsibly and sustainably.

Overall, we remain confident of delivering 25% revenue growth for the full year with stable margins."

(Mn.)

Revenue for Q1 FY27

₹3,297

YoY ▲ **59.1%**

EBITDA for Q1 FY27

₹1,131

YoY ▲ **122.1%**

PAT for Q1 FY27

₹750

YoY ▲ **70.4%**

Q1 FY27 Financial Performance – Key Metrics

ACUTAAS
You and us: chemistry's apex

Revenue from Operations

(₹ Mn.)



EBITDA & EBITDA Margin

(₹ Mn)



PAT

(₹ Mn.)



Q1 FY27 Earnings & Business Highlights

Pharma Intermediates

CDMO continues strong growth momentum; Core Advanced intermediate business delivered robust growth

Specialty Chemicals

Strong growth in BFC offset by muted performance in commodity chemicals

EBITDA Margins

Driven by better product mix and operational efficiencies

PAT Margin

PAT margins were driven by strong EBITDA margins which was offset by lower other income

Q1 FY27 Financial Performance – P&L Statement

Particulars (Rs. Mn)	Q1FY27	Q1FY26	*YoY*	Q4FY26	*QoQ*
Revenue from Operations	**3,297**	**2,072**	*59.1%*	**4,328**	*-23.8%*
COGS	1,388	969		1,644	
Gross Profit	**1,909**	**1,103**	*73.0%*	**2,683**	*-28.8%*
Gross Margin	*57.9%*	*53.2%*		*62.0%*	
Employee Benefits Expenses	396	251		333	
Other Expenses	383	344		515	
Total Expenses	**778**	**595**	*31.0%*	**848**	*-8.2%*
EBITDA	**1,131**	**509**	*122.1%*	**1,835**	*-38.4%*
EBITDA Margin	34.3%	24.6%		42.4%	
Depreciation and amortization	98	81		96	
PBIT	**1,032**	**428**	*141.4%*	**1,739**	*-40.6%*
Finance costs	11	6		12	
Other Income	18	159		111	
PBT	**1,039**	**581**	*78.9%*	**1,838**	*-43.5%*
Tax Expense	289	141		495	
PAT	**750**	**440**	*70.4%*	**1,343**	*-44.2%*
PAT Margin	*22.7%*	*21.2%*		*31.0%*	

Financial Performance over the years – Key Metrics

ACUTAAS
You and us: chemistry's apex

Revenue from Operations- Growth Trends (₹ Mn.)



EBITDA and EBITDA Margins (₹ Mn. & %)



Revenue – by Business Verticals (%)



Returns Profile# (%)



PAT and PAT Margins (₹ Mn & %)



Note: PAT for FY24 is adjusted for Exceptional Items

ROE and ROCE adjusted for Cash & Cash Equivalents, Exceptional Items, CWIP

Financial Performance over the years - Profit and Loss

Particulars (₹ Mn.)	FY21	FY22	FY23	FY24	FY25	FY26
Revenue from Operations	3,406	5,201	6,167	7,175	10,069	13,394
Other Income	14	28	43	75	169	416
Total Income	**3,420**	**5,229**	**6,210**	**7,250**	**10,238**	**13,810**
Cost of materials consumed	1,749	2,823	3,459	4,402	5,698	5,950
Changes in Inventories[1]	48	(95)	(150)	(285)	(176)	(290)
Employee benefits expenses	210	414	488	631	837	1,176
Finance cost	56	64	24	59	62	33
Depreciation and amortisation expenses	42	101	123	161	266	360
Other expenses	598	1,008	1,144	1,142	1,390	1,754
Total Expense	**2,703**	**4,315**	**5,088**	**6,110**	**8,077**	**8,982**
Profit before tax and exceptional items	**717**	**914**	**1,122**	**1,140**	**2,162**	**4,827**
Exceptional profit / (loss)	-	-	-	(321)	-	-
Tax expense	177	195	289	332	557	1,264
Profit for the year	**540**	**719**	**833**	**487**	**1,604**	**3,564**

[1] *Changes in inventories of finished goods, traded goods and work-in-progress*

Financial Performance over the years - Balance Sheet

ACUTAAS
You and us: chemistry's apex

Assets (₹ Mn.)	FY21	FY22	FY23	FY24	FY25	FY26
Property, plant and equipment	1,422	1,584	1,844	3,229	4,629	5,828
Right of use assets	184	194	374	372	424	505
Capital work-in-progress	2	30	255	1,254	1,303	3,324
Goodwill	-	-	203	568	568	1,043
Other intangible assets	257	267	211	103	83	72
Investments	14	17	17	2	2	2
Other financial assets	27	108	65	26	49	82
Current tax assets (net)	-	49	32	25	2	-
Other non-current assets	64	97	129	447	517	171
Total non-current assets	**1,970**	**2,346**	**3,130**	**6,026**	**7,577**	**11,027**
Inventories	604	1,122	1,192	1,567	1,799	2,313
Trade receivables	1,207	1,637	2,303	2,064	2,905	3,626
Cash and cash equivalents	27	103	305	297	1,852	2,156
Other bank balances	-	893	281	236	637	93
Loans	3	6	13	16	22	26
Other current assets	321	481	445	753	701	599
Total current assets	**2,162**	**4,291**	**4,571**	**4,958**	**7,916**	**8,813**
Total assets	**4,133**	**6,589**	**7,669**	**10,959**	**15,493**	**19,840**

Liabilities & Equity (₹ Mn.)	FY21	FY22	FY23	FY24	FY25	FY26
Shareholder's equity	**1,669**	**5,223**	**5,939**	**6,828**	**13,201**	**17,108**
Financial Liabilities	726	6	6	1,136	48	91
Provisions	44	4	7	13	25	46
Deferred tax liabilities (net)	33	63	88	130	196	287
Total non-current liabilities	**803**	**73**	**101**	**1,280**	**269**	**424**
Borrowings	640	3	30	1,030	82	265
Trade payables	848	1,184	1420	1,346	1,561	1,539
Other current liabilities	151	46	64	344	135	124
Provisions	10	60	114	132	245	325
Current tax liabilities (net)	11	-	-	-	-	55
Total current liabilities	**1,660**	**1,293**	**1,628**	**2,852**	**2,023**	**2,308**
Total liabilities	**2,463**	**1,366**	**1,730**	**4,131**	**2,292**	**2,732**
Total equity and liabilities	**4,133**	**6,589**	**7,669**	**10,959**	**15,493**	**19,840**

Shareholder Information

Shareholding as on 30th June 2026



Source: NSE

Share Information as on 30th June 2026

NSE Ticker	**ACUTAAS**
BSE Ticker	**543349**
Market Cap (₹ Cr.)	**28,869**
Shares Outstanding	**8,18,71,122**
3M ADTV (Shares)	**4,86,444**
3M ADTV (₹ Cr.)	**82.4**
Industry	**Specialty Chemicals**

Source: NSE

Safe Harbor

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceutical and chemical industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

Contact Us

For more information please contact:

Acutaas Chemicals Limited

Ekta Srivastava
Company Secretary & Compliance Officer
cs@acutaas.com

Rahul Thakur
Senior Manager – Investor Relations
Rahul.thakur@acutaas.com